vs
Kennedy-Wilson Holdings, Inc.（KW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Kennedy-Wilson Holdings, Inc.的1.7倍（$207.3M vs $120.6M），Kennedy-Wilson Holdings, Inc.净利率更高（48.1% vs -62.0%，领先110.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -11.0%），Kennedy-Wilson Holdings, Inc.自由现金流更多（$-55.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -6.0%）
肯尼迪-威尔逊控股是一家房地产投资企业，公司总部位于美国加利福尼亚州比弗利山庄，业务覆盖全球多地房地产领域的投资与运营相关业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KW vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.6M | $207.3M |
| 净利润 | $58.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 57.3% | -54.7% |
| 净利率 | 48.1% | -62.0% |
| 营收同比 | -11.0% | 25.9% |
| 净利润同比 | 32.7% | 3.5% |
| 每股收益（稀释后） | $0.22 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $120.6M | $207.3M | ||
| Q3 25 | $116.4M | $159.9M | ||
| Q2 25 | $135.7M | $166.5M | ||
| Q1 25 | $128.3M | $139.3M | ||
| Q4 24 | $135.5M | $164.6M | ||
| Q3 24 | $127.5M | $139.5M | ||
| Q2 24 | $132.0M | $147.0M | ||
| Q1 24 | $136.4M | $108.8M |
| Q4 25 | $58.0M | $-128.6M | ||
| Q3 25 | $-10.2M | $-180.4M | ||
| Q2 25 | $5.6M | $-115.0M | ||
| Q1 25 | $-29.6M | $-151.1M | ||
| Q4 24 | $43.7M | $-133.2M | ||
| Q3 24 | $-66.8M | $-133.5M | ||
| Q2 24 | $-48.3M | $-131.6M | ||
| Q1 24 | $37.7M | $-170.7M |
| Q4 25 | 57.3% | -54.7% | ||
| Q3 25 | -6.2% | -106.9% | ||
| Q2 25 | 7.4% | -64.8% | ||
| Q1 25 | -26.9% | -102.6% | ||
| Q4 24 | 36.7% | -74.3% | ||
| Q3 24 | -60.8% | -94.6% | ||
| Q2 24 | -45.5% | -79.1% | ||
| Q1 24 | 47.2% | -151.9% |
| Q4 25 | 48.1% | -62.0% | ||
| Q3 25 | -8.8% | -112.8% | ||
| Q2 25 | 4.1% | -69.0% | ||
| Q1 25 | -23.1% | -108.5% | ||
| Q4 24 | 32.3% | -80.9% | ||
| Q3 24 | -52.4% | -95.7% | ||
| Q2 24 | -36.6% | -89.5% | ||
| Q1 24 | 27.6% | -156.8% |
| Q4 25 | $0.22 | $-1.28 | ||
| Q3 25 | $-0.15 | $-1.81 | ||
| Q2 25 | $-0.05 | $-1.17 | ||
| Q1 25 | $-0.30 | $-1.57 | ||
| Q4 24 | $0.24 | $-1.34 | ||
| Q3 24 | $-0.56 | $-1.40 | ||
| Q2 24 | $-0.43 | $-1.52 | ||
| Q1 24 | $0.19 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $-80.0M |
| 总资产 | $6.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $184.5M | $421.0M | ||
| Q3 25 | $382.6M | $202.5M | ||
| Q2 25 | $309.1M | $176.3M | ||
| Q1 25 | $356.6M | $127.1M | ||
| Q4 24 | $217.5M | $174.0M | ||
| Q3 24 | $367.1M | $150.6M | ||
| Q2 24 | $366.5M | $480.7M | ||
| Q1 24 | $541.9M | $112.3M |
| Q4 25 | $1.5B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.6B | $151.3M | ||
| Q1 25 | $1.6B | $144.2M | ||
| Q4 24 | $1.6B | $255.0M | ||
| Q3 24 | $1.6B | $346.8M | ||
| Q2 24 | $1.7B | $432.4M | ||
| Q1 24 | $1.7B | $140.3M |
| Q4 25 | $6.6B | $1.5B | ||
| Q3 25 | $6.7B | $1.2B | ||
| Q2 25 | $6.8B | $1.3B | ||
| Q1 25 | $7.2B | $1.3B | ||
| Q4 24 | $7.0B | $1.5B | ||
| Q3 24 | $7.4B | $1.5B | ||
| Q2 24 | $7.5B | $1.6B | ||
| Q1 24 | $7.7B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-55.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | -45.8% | -48.6% |
| 资本支出强度资本支出/营收 | 55.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.20× | — |
| 过去12个月自由现金流最近4个季度 | $-103.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $11.4M | $-99.8M | ||
| Q3 25 | $-7.6M | $-91.4M | ||
| Q2 25 | $42.0M | $-108.3M | ||
| Q1 25 | $-51.9M | $-166.5M | ||
| Q4 24 | $55.1M | $-79.3M | ||
| Q3 24 | $-5.6M | $-67.0M | ||
| Q2 24 | $36.7M | $-77.0M | ||
| Q1 24 | $-5.6M | $-190.7M |
| Q4 25 | $-55.2M | $-100.8M | ||
| Q3 25 | $-18.0M | $-92.7M | ||
| Q2 25 | $29.4M | $-110.7M | ||
| Q1 25 | $-59.7M | $-167.8M | ||
| Q4 24 | $-76.5M | $-79.5M | ||
| Q3 24 | $-27.7M | $-68.6M | ||
| Q2 24 | $-500.0K | $-79.0M | ||
| Q1 24 | $-57.1M | $-193.9M |
| Q4 25 | -45.8% | -48.6% | ||
| Q3 25 | -15.5% | -58.0% | ||
| Q2 25 | 21.7% | -66.5% | ||
| Q1 25 | -46.5% | -120.5% | ||
| Q4 24 | -56.5% | -48.3% | ||
| Q3 24 | -21.7% | -49.2% | ||
| Q2 24 | -0.4% | -53.7% | ||
| Q1 24 | -41.9% | -178.2% |
| Q4 25 | 55.2% | 0.5% | ||
| Q3 25 | 8.9% | 0.8% | ||
| Q2 25 | 9.3% | 1.5% | ||
| Q1 25 | 6.1% | 1.0% | ||
| Q4 24 | 97.1% | 0.1% | ||
| Q3 24 | 17.3% | 1.2% | ||
| Q2 24 | 28.2% | 1.4% | ||
| Q1 24 | 37.8% | 3.0% |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.50× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
